Molecular Diagnostics VL

Breaking Down Barriers: Feasibility of Internet-based Genetic Testing for Men with Metastatic Prostate Cancer, The GENTleMEN Study -Heather Cheng

Details
Heather Cheng and Andrea Miyahira discuss the GENTleMEN study, which explored the feasibility of an internet-based, cost-free genetic testing program for men with metastatic prostate cancer. The study aimed to provide genetic testing to patients with advanced disease by removing barriers to access and cost and was launched in 2016 after research suggested that 25% of metastatic prostate cancer tum...

Genomic Health Literacy in Treatment Decision-Making for Prostate Cancer - Elisabeth Heath

Details
Elisabeth Heath joins Alicia Morgans in a discussion on a patient-centered approach to discussing genetic and genomic testing for prostate cancer. Both Drs. Heath and Morgans recommend breaking down the information given to our patients into multiple visits and more easily digestible segments rather than sharing everything in one office visit. They speak to the importance of supporting our patient...

The Caris Precision Oncology Alliance™ - Chadi Nabhan

Details
Chadi Nabhan joins Charles Ryan to discuss The Caris Precision Oncology Alliance™ (POA), which focuses on precision oncology to optimize clinical care and outcomes of patients with cancer. The Precision Oncology Alliance gathers real-world data from patients that undergo molecular tumor profiling across the spectrum of solid malignancies and feeds the data into a large database that can be accesse...

How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi

Details
Kim Chi presents an overview of how to read a genomics testing report during APCCC 2022. His presentation includes a discussion of prostate cancer-relevant genes, reading the FoundationOne CDx test, and more. Chi explains the importance of understanding the intricacies of the genomics report and its limitations given that tumor genomics is now a standard part of the workup for patients with advanc...

Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron

Details
Jason Hafron, MD, joins Alicia Morgans, MD, MPH in a conversation on operationalizing genomic testing in clinical practice, towards supporting the use of PARP inhibitors in the appropriate patients. Dr. Hafron emphasizes the key to this success begins with the implementation of clinical pathways. With streamlined accurate clinical pathways, we can speed up the process and provide care to the patie...

BRCA1/2 and Beyond - Molecular Diagnostic Testing and Treatments with PARP Inhibitors for mCRPC - Joaquin Mateo

Details
In May 2020, the United States Food and Drug Administration approved olaparib for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Efficacy was investigated in the PROfound study, a pr...

Pembrolizumab in mCRPC Patients with Microsatellite Instability High (MSI-H) Detected by Circulating Tumor DNA - Pedro Barata

Details
Joining Alicia Morgans, MD, MPH, is Pedro Barata, MD, MSc, a co-author of the paper titled, "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability-high (MSI-H) detected by circulating tumor DNA." Dr. Barata provides the background behind the multi-institutional case series explaining that the use of liquid biopsy in identifying metastatic prostate cancer...

The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor

Details
Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss the US Federal Drug Administration (FDA) recent approval of the FoundationOne® Liquid CDx biopsy test that informs precision medicine in mCRPC. This is a companion diagnostic that serves as a predictive biomarker to identify patients who may benefit from targeted therapies including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibito...

Intersection of Germline and Somatic Testing - Colin Pritchard and Heather Cheng

Details
Colin Pritchard, MD, PhD, Heather Cheng, MD, PhD, and Petros Grivas, MD, PhD, join Alicia Morgans, MD, MPH, to discuss the increasing role of molecular diagnostics and testing in genitourinary cancers. Dr. Pritchard begins by highlighting the advantages of the University of Washington and Seattle Cancer Care Alliance’s GU molecular tumor board. By providing clinicians the opportunity to discuss tu...

The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study - Mary-Ellen Taplin

Details
Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans to discuss the ProGen study. A randomized controlled trial that aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer. This...